Every material Form 8-K Revvity filed with the SEC in 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Revvity, Inc. reported third quarter 2026 revenue of $729 million and GAAP EPS from continuing operations of $0.56, compared to $699 million and $0.41 a year ago. The company raised its full year 2026 pro forma guidance, forecasting total revenue of approximately $2.86 billion and pro forma adjusted EPS of $5.40-$5.45. Additionally, the company is holding its Investor Day on November 13, 2026.
Revenue for the third quarter ended October 4, 2026 was $729 million, with pro forma revenue of $710 million representing 7% pro forma organic growth.
GAAP EPS from continuing operations was $0.56, while adjusted EPS from continuing operations reached $1.38.
Full year 2026 pro forma guidance forecasts total revenue of approximately $2.86 billion and pro forma adjusted EPS of $5.40-$5.45.
Revvity reported second-quarter 2026 revenue of $730 million, up from $720 million a year earlier, and GAAP EPS from continuing operations of $0.48 versus $0.47. The company raised its full-year 2026 guidance and agreed to sell its China Immunodiagnostics business for up to $200 million, a deal it expects to close by the end of 2027.
Q2 2026 revenue was $730 million, versus $720 million in Q2 2025; adjusted EPS from continuing operations was $1.41, versus $1.18
Adjusted EPS includes approximately $0.11 from tariff-related refunds, according to the filing
Full-year 2026 pro forma adjusted EPS guidance is $5.30-$5.40, and pro forma revenue guidance is $2.83-$2.86 billion, excluding China IDX
China IDX sale for up to $200 million, signed July 31, 2026; expected to close by the end of 2027, subject to conditions and regulatory approvals
Revvity reported first-quarter 2026 revenue of $711 million, up from $665 million a year earlier, and adjusted EPS of $1.06, up from $1.01. The company also said it intends to divest its China Immunodiagnostics business, under a letter of intent for up to $200 million, and updated its full-year 2026 guidance on a pro forma basis.
Q1 2026 revenue was $711 million vs $665 million a year earlier; GAAP EPS from continuing operations was $0.37 vs $0.35.
Adjusted operating income was $168 million vs $170 million, and adjusted operating margin was 23.6% vs 25.6%.
Full-year 2026 pro forma guidance: total revenue of $2.81-$2.84 billion and pro forma adjusted EPS of $5.20-$5.30.
China Immunodiagnostics was about 6% of 2025 revenue; a letter of intent was signed April 16, 2026, with a definitive agreement expected in Q2 2026 and completion expected in 2027.
Revvity reported fourth-quarter 2025 revenue of $772 million, up 6% from a year earlier, and adjusted EPS from continuing operations of $1.70, up from $1.42. For full-year 2025, revenue rose to $2.86 billion and adjusted EPS reached $5.06, though GAAP EPS fell to $2.07 from $2.20. The company also initiated 2026 guidance, which calls for revenue of $2.96 billion to $2.99 billion and adjusted EPS of $5.35 to $5.45.
Q4 2025 GAAP EPS was $0.87 vs. $0.78 a year earlier; GAAP operating income fell to $112 million from $119 million.
Diagnostics Q4 revenue rose 10% to $390 million; Life Sciences Q4 revenue rose 2% to $382 million.
Full-year 2025 revenue was $2,856 million vs. $2,755 million in 2024; GAAP EPS was $2.07 vs. $2.20.
2026 guidance: revenue of $2.96 billion to $2.99 billion, organic revenue growth of 2% to 3%, and adjusted EPS of $5.35 to $5.45.
Revvity said it expects full-year 2025 adjusted earnings per share to exceed the upper end of its $4.90-$5.00 guidance from October 27, 2025. It also preliminarily estimated fourth-quarter revenue of approximately $772 million and full-year 2025 revenue of approximately $2,855 million, with final results due February 2, 2026. For shareholders, this is an early signal that profit and revenue are running ahead of the prior outlook, though the figures remain preliminary until the full release.
Full-year 2025 adjusted EPS now expected to exceed the upper end of the $4.90-$5.00 guidance
Fourth-quarter 2025 revenue expected at approximately $772 million, up approximately 6% reported and 4% organic
Full-year 2025 revenue expected at approximately $2,855 million, up approximately 4% reported and 3% organic
Full fourth-quarter and full-year 2025 results and earnings call scheduled for February 2, 2026
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Revvity filing is on SEC EDGAR ↗. 8-K briefs of other companies →